The phase II SABR-COMET study has indicated that stereotactic ablative radiotherapy prolongs overall and progression-free survival versus palliative treatment in patients with up to five oligometastases.
Approximately one-fifth of patients with RAS and BRAF wild-type metastatic colorectal cancer derive clinical benefit from rechallenge with cetuximab plus irinotecan, Italian researchers report.
In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.
Patients whose colon cancers are detected by routine screening have fewer postoperative complications than individuals whose cancers are diagnosed outside of a national programme, study findings indicate.
Minimally invasive liver surgery is associated with less postoperative morbidity, fewer major complications, and shorter hospital stays than open surgery among patients with colorectal liver metastases, Italian researchers report.
Phase III trial results indicate that third- or later-line treatment with fruquintinib leads to significantly improved overall survival in Chinese patients with metastatic colorectal cancer.
We cover three studies of colorectal cancer surveillance, one evaluating the relationship between adenomas at colonoscopy and the long-term incidence of cancer, while the other two investigate whether higher-intensity post-surgery follow-up improves outcomes.
Oxaliplatin-based hyperthermic intraperitoneal chemotherapy after cytoreductive surgery does not improve the survival of colorectal cancer patients with peritoneal carcinomatosis, the PRODIGE 7 investigators report.
The cost of metastatic colorectal cancer treatment in the USA is significantly more expensive than in Canada but does not achieve a greater survival benefit among patients, highlight findings reported at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA.
Women have an increased risk for adverse events associated with fluorouracil-based chemotherapy for colorectal cancer, suggests an analysis of the PETACC-3 trial.
The presence of the BRAF V600E mutation in colorectal liver metastases is associated with a worse prognosis and increased risk for recurrence, according to findings from an international retrospective cohort study.
Treatment with a modified XELIRI regimen offers an alternative to standard second-line therapy with FOLFIRI in patients with metastatic colorectal cancer, research conducted in Asia shows.
Researchers report “encouraging” tolerability and efficacy results from a phase Ia trial of the oral phosphatidylinositol 3-kinase α–selective inhibitor alpelisib among patients with PIK3CA-altered advanced solid tumors.
CheckMate 142 findings point to a role for dual PD-1 and CTLA-4 inhibition with nivolumab and ipilimumab in patients with previously treated metastatic colorectal cancer that is DNA mismatch repair-deficient or has high microsatellite instability.
Researchers do not recommend the addition of 18F-fluorodeoxyglucose–positron emission tomography/computed tomography to a standard 3-year monitoring strategy for patients with stage II perforated, stage III, or stage IV colorectal cancer at high risk for recurrence.
Maintenance treatment with bevacizumab monotherapy following induction chemotherapy has no benefit for metastatic colorectal cancer patients, PRODIGE 9 trial findings show.
A diet rich in foods with a high inflammatory potential is associated with a significant increase in the risk for colorectal cancer, say US researchers who collated information from more than 120,000 adults followed up over 26 years.
Researchers have warned that underuse of mismatch repair deficiency testing “is a persistent and pervasive problem” in the USA, even among young adults with colorectal cancer where its use is unequivocally recommended.